Skip to main content
Alteogen Inc. logo

Alteogen Inc. — Investor Relations & Filings

Ticker · 196170 ISIN · KR7196170005 KO Professional, scientific and technical activities
Open in API
Filings indexed 293 across all filing types
Latest filing 2026-02-02 Earnings Release
Country KR South Korea
Listing KO 196170

About Alteogen Inc.

http://www.alteogen.com/

Alteogen Inc. is a biopharmaceutical company focused on the development and commercialization of next-generation biologics. The company's core activities are centered on its proprietary platform technologies. These include Hybrozyme™, a novel recombinant human hyaluronidase (ALT-B4) technology that enables the conversion of intravenous (IV) therapies to subcutaneous (SC) formulations, enhancing patient convenience. Additionally, Alteogen develops long-acting biobetters utilizing its NexP™ fusion technology, proprietary antibody-drug conjugates (ADCs), and antibody biosimilars. The company's pipeline is aimed at creating therapies with enhanced efficacy and delivery methods for serious diseases.

Recent filings

Filing Released Lang Actions
영업(잠정)실적(공정공시)
Earnings Release Classification · 100% confidence The document is a 'Provisional Earnings Release' (영업(잠정)실적) from Alteogen, which provides key financial highlights (revenue and operating profit) for the fiscal year 2025 compared to 2024. It explicitly states that these are preliminary figures provided for investor convenience before the final audit. This fits the definition of an Earnings Release (ER), which is the initial announcement of periodical financial results. FY 2025
2026-02-02 Korean
투자판단관련주요경영사항 (인간 히알루로니다제 제품(ALTB4) 독점적 라이선스 계약 체결)
Regulatory Filings Classification · 95% confidence The document is a formal regulatory filing from a Korean company (Alteogen) regarding a 'Major Management Matter' (투자판단 관련 주요경영사항), specifically announcing a licensing agreement for their ALT-B4 technology with GSK. This type of disclosure is a standard regulatory filing in the Korean market (DART system) used to inform investors of material business developments, such as technology exports or significant contracts. Since it is a specific announcement of a material event rather than a periodic report, a conference call transcript, or a simple report publication notice, it falls under the 'Regulatory Filings' category.
2026-01-20 Korean
기업설명회(IR)개최
Regulatory Filings Classification · 95% confidence The document is a formal announcement regarding an upcoming Investor Relations (IR) event (a corporate presentation at the J.P. Morgan Healthcare Conference). It provides details such as the date, location, purpose, and method of the event. Since it is an announcement of an event/presentation rather than the presentation slides themselves, and it is a short regulatory notice, it falls under the category of a general regulatory filing or announcement regarding company activities.
2026-01-08 Korean
대표이사변경
Board/Management Information Classification · 100% confidence The document is a formal announcement regarding a change in the company's Chief Executive Officer (대표이사변경). It details the outgoing and incoming CEOs, the reason for the change, the date of the board resolution, and the professional background of the new appointee. This falls directly under the category of Board/Management Information.
2025-12-26 Korean
주주총회소집결의 (임시주주총회)
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a notice of convening a shareholders' meeting (임시주주총회) scheduled for December 8, 2025. It includes details such as date, time, location, agenda items (including conditional delisting from KOSDAQ and transfer to KOSPI, and changes to director remuneration limits), and mentions electronic voting procedures. The document is short (840 characters) and serves as an announcement to shareholders about the meeting rather than the meeting materials or results. Therefore, it fits the category of a Proxy Solicitation & Information Statement (PSI), which includes materials sent to shareholders to provide information and request votes for meetings.
2025-11-06 Korean
주주명부폐쇄기간또는기준일설정
Regulatory Filings Classification · 95% confidence The document is a brief announcement regarding the setting of a record date and closure period for the shareholder register in preparation for an extraordinary general meeting. It includes specific dates and legal references but does not contain financial data or detailed reports. This type of announcement is related to shareholder meeting logistics rather than the meeting materials or voting results themselves. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2025-11-06 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.